title: [A case report of a well-differentiated neuroendocrine tumor in which sunitinib treatment resulted in stable disease].
abstract: A 52-year-old woman had a primary neuroendocrine tumor, Grade 2(NET G2)with multiple liver metastases and a mesenteric tumor. Since no drugs were approved for NET at that time in Japan, we treated her with sunitinib after approval by the Ethics Committee of Mie University Hospital and obtaining informed consent. Sunitinib was administered at a daily dose of 37.5mg/day, but the dose was reduced to 12.5mg/day because of thrombocytopenia(G3)and neutropenia(G3). CT revealed stable disease after 3 months of treatment, but disease progression was observed after 11 months. The non-hematological toxicity was hypertension(G3), which was controlled with antihypertensive agents. Although there are no previous reports of the treatment of well-differentiated NET with sunitinib in Japan, sunitinib may be effective against this disease.
authors.affiliation: Dept. of Hematology and Medical Oncology, Mie University Hospital, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tamaru
authors.forename: Toshiro
authors.initials: T
authors.lastname: Mizuno
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Oda
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Sugawara
authors.forename: Kanako
authors.initials: K
authors.lastname: Saito
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kageyama
authors.forename: Katsunori
authors.initials: K
authors.lastname: Uchida
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imai
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Matsuoka
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Katayama
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002454:Cell Differentiation; D018450:Disease Progression; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy*; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib